Brave Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brave Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-261	Closed	-$274K	–	177
2024 Q3	$274K	Hold	261	–	–	0.07%	113
2024 Q2	$274K	Hold	261	–	–	0.07%	104
2024 Q1	$251K	Hold	261	–	–	0.07%	111
2023 Q4	$229K	Sell	261 -50	-16%	-$41.2K	0.06%	116
2023 Q3	$256K	Hold	311	–	–	0.08%	101
2023 Q2	$223K	Hold	311	–	–	0.07%	115
2023 Q1	$256K	Hold	311	–	–	0.08%	102
2022 Q4	$224K	Hold	311	–	–	0.08%	116
2022 Q3	$214K	Buy	+311	New	+$196K	0.11%	111
2022 Q2	–	Sell	-311	Closed	-$217K	–	162
2022 Q1	$217K	Buy	+311	New	+$197K	0.07%	131
2016 Q4	–	Sell	-420	Closed	-$169K	–	282
2016 Q3	$169K	Sell	420 -30	-7%	-$12K	0.11%	136
2016 Q2	$157K	Buy	+450	New	+$173K	0.11%	144

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brave Asset Management's REGN Position: Q4 2024 in Review

Brave Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 261 shares — an estimated $274K sold.

Brave Asset Management first reported a position in REGN in Q2 2016 and held it in 12 quarters. The position peaked at $274K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Brave Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Brave Asset Management sold 261 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $274K.
Brave Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 12 quarters.
Brave Asset Management's Regeneron Pharmaceuticals position peaked at $274K in Q3 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Brave Asset Management's 13F filing for Q4 2024, filed 14 Jan 2025.